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Both rhinitis (ARIA) and asthma (GINA) guidelines recommend allergen-specific immunotherapy
(SIT) tailored to the specific levels of severity of each disease. Real world studies evaluating
congruence between these recommendations and prescribing practice in the single patient with
comorbidity are lacking.
An observational polycentric study was carried out in 518 patients recruited from 34 allergy
centers throughout Italy. A questionnaire was administered to each consecutive patient over
a span of four months.
Taking into account guideline recommendations for both diseases, concomitant in the same
patient, three subsets resulted: patients not eligible for SIT (11%); patients eligible for SIT for
one disease only (60%); patients eligible for SIT for both diseases (29%). SIT was prescribed in
257 (49.6%) subjects. The level of SIT prescription was about 50% in all three groups. Consistent
with the ARIA guidelines, a correlation between the prescription of SITand the severity of rhinitis
was documented (rZ 0.87; pZ 0.001). An association with asthma severity was found
(pZ 0.02), but the trend was inconsistent with the GINA recommendations. Young age was the
most important factor for SIT prescription both in the eligible for one disease and in the eligible
for both diseases subset. The tendency towards worsening of symptoms was a factor for SIT in
the eligible for one disease subset.
In mite allergic patients with rhinitis and asthma comorbidity, the severity of rhinitis and the
young age are the most important factors driving the SIT prescription. The congruence of SIT
prescription was better for the ARIA than GINA guidelines.
ª 2011 Elsevier Ltd. All rights reserved.15965693; fax: þ39 0715963253.
daliriuniti.marche.it (L. Antonicelli).
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1442 L. Antonicelli et al.Introduction Materials and methodsAlthough a high level of comorbidity among allergic (and
non-allergic) diseases of the upper and lower airways is
widely acknowledged,1e3 the vast majority of available
therapies are single disease-oriented. The international
guidelines both for allergic rhinitis (ARIA) and for asthma
(GINA) take this into account and prescribe therapies
geared towards the severity of symptoms of each single
disease.4
Montelukast, omalizumab and specific immunotherapy
(SIT) are exceptions to this approach, as they are single
therapies, which are beneficial for both diseases.
As consequences of their prevalent efficacy on asthma
and of the elevated cost of omalizumab, the first two
medications have been adopted by the Italian version of
international guidelines for the asthma treatment only.
For SIT this is not the case, because recommendations
tailored to the specific levels of severity of both rhinitis and
asthma were produced, consistent with the results of the
single disease related meta-analyses.5,6
The Italian edition of the ARIA guidelines (2005)
recommend SIT for intermittent moderate-severe rhinitis
and both mild and moderate-severe persistent rhinitis,7
while the Italian edition of the GINA guidelines (2006)
recommend its administration for mild persistent and
moderate persistent asthma.8 The problem of the
concomitance of both disease, with different levels of
severity in the same patient, was not openly handled.
Few studies have investigated the congruence of SIT
prescription with international guidelines in the real world
and the quality of their results is poor.
One German study highlighted the differences between
clinical practice and guideline recommendations,9 while
another performed in asthmatics, assessed according to
GINA guidelines, documented that the prescription of SIT
fell as the severity of bronchial asthma increased.10 In yet
another, done in a specialist setting, SIT was reported to
have been prescribed for moderate-severe rhinitis (35%),
rhinitis and asthma (34%) and bronchial asthma (31%) but
did not provide further information.11
While disease-centred guidelines underline the severity
of the disease, the position papers focusing on SIT empha-
size the importance of the patient-centred approach. In
order to optimize the specificity and results of SIT, certain
features (in particular, sensitization to a single allergen,
the early commencement of SIT, the preventive effect of
SIT on the progression from rhinitis to asthma) were focused
on in the decision making process that eventually led to SIT
prescription.12e14
The three-fold aim of our study was: (1) to investigate
the congruence of SIT prescription with the ARIA and GINA
guideline recommendations in mite allergic patients with
both rhinitis and asthma, (2) to evaluate the interplay
between the recommendations provided by disease-
oriented guidelines and SIT-oriented position papers and
its influence on SIT prescription, and (3) to identify those
factors which favour the prescription of subcutaneous
immunotherapy (SCIT) over its sublingual alternative (SLIT)
and vice versa in Italy, where both are commercially
available.Study design
multicentre, observational, cross-sectional study, involving
allergy and pneumology units throughout Italy was carried
out.
The units were selected through emails enlisting their
participation in the survey sent to 570 members of the
AAITO (Italian Association of Territorial and Hospital Aller-
gists and Immunologists). Forty-three centers joined the
survey, nine subsequently dropped out for reasons unre-
lated to the study.
During their scheduled doctor’s appointment, patients
were invited by their doctors to enrol for the study and
those consenting to do so signed an informed consent form
and completed a self-administered questionnaire.
A two-share standard questionnaire was used.
The patient share of the questionnaire collected basic
demographic details (age, sex, etc.) and clinical details
(predominant symptoms). This share of the questionnaire
was filled in by patients prior to being examined, without
doctor supervision.
At the end of the appointment, the physician completed
his/her share of the questionnaire, which was designed to
gather specific clinical details and factors supporting the
decision to prescribe SIT and divided into patient and non-
patient related features.
The first domain listed the level of education, smoking
habits, the mite allergic mono/polysensitisation, the
concomitant disease, the physician’s assessment of both
the evolution of symptoms and efficacy of current therapy.
The second domain reported the physician’s specialty,
the stage of the doctorepatient relationship (first time or
follow-up visit) and the cost of the treatment.
In Italy the reimbursement of SIT varies, depending on
the Regional Health Service. SIT is either fully charged to
the patient in some regions or is partially or completely
subsidized by the Health Service in others.
Concerning the severity of rhinitis and asthma, the ques-
tionnaire was completed by physicians prior to the decision
to or not to treat and was designed to collect guideline-
orientated data. However, in order to maintain physician
objectivity the severity index of both diseases remained
undisclosed during completion of the questionnaire, thereby
ensuring as far as possible that the decision was not solely
based on the unequivocal evidence of disease severity.
The severity of the both diseases was later classified by
a peer, applying the rhinitis and asthma-severity guidelines
scale. All data were collected from September 1st 2007 to
December 31st 2007.
The study was approved by the Ethics Committee of the
Coordinating Unit.
Patients
All consecutive patients, aged 14 and older, attending
a specialist unit, with a history of rhinitis and asthma
comorbidity and evidence of house dust mite allergy, were
eligible for the study.
Table 1 Demographic characteristics and clinical data of
the study participants.
Sample size 556 patients
Gender
Male 59.1%
Female 40.9%
Age (years)
Mean 33 years
Range 14e76 years
Median 32 years
Geographic area
North 15 centers
Centre 8 centers
South 11 centers
Smoking status
Never smoked 76.6%
Current 13.2%
Former 10.2%
Education
None 0.4%
Elementary school 6.4%
Middle school 30%
High school 48.4%
University ordinary degree 3.5%
Honours degree 10%
Master/specialization 1.3%
Sensitization
Mite mono-sensitized 31.6%
Mite plus other sensitizations 68.4%
Comorbidity
Sinusitis 13.1%
Nasal polyps 4.0%
GERD 10.5%
Specialist’s belief about the tendency
of the disease
No worsening 74.1%
Worsening 25.9%
Current drug therapy
Yes 65.9%
No 34.1%
Comorbidities with a prevalence greater than 4% are tabulated.
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controlled for as part of the inclusion criteria.
A diagnosis of mite allergy was admitted, provided that
at least the following two conditions were fulfilled:
a history consistent with mite allergy (predominant symp-
toms, seasonality of symptoms and exacerbating factors)
and a positive skin prick test for mite. Skin prick testing
with a panel of the most prominent inhalant allergens in
Italy was performed in all patients, with a positive and
negative control. A mean wheal diameter  3 mm was
considered positive. Patients were enrolled even if they
were positive to more than one of aeroallergen skin tests.
Rhinitis and asthma severity assessment
Consistent with the ARIA guidelines,7 the severity of
rhinitis was evaluated by combining the duration of
symptoms and the disease’s impact on patient quality
of life and classified as follows: intermittent (<4 days/
week or <4 weeks/year) and persistent (>4 days/week
and >4 weeks/year). Rhinitis was diagnosed as moderate-
severe in patients who replied “yes” to one or more of the
following items: abnormal sleep; impairment of daily work
or school; impairment of leisure activities; and presence of
troublesome symptoms. Rhinitis was classified as mild in
patients who replied “no” to all of the above listed items.
In accordance with the GINA classification algorithm
(2006), the severity of asthma was ascertained using the
grid sheet, describing the patient’s level of symptoms and
his/her level of treatment.8
Statistics
Statistical analysis of the data yielded by the questionnaire
was done using SPSS 10.0 for Windows. The bivariate
analyses done to compare the rates of prevalence among
groups and the analysis of variance done to compare
continuous variability among groups were conducted by chi-
square test.
Logistic regression models designed to estimate the
association among variables of effect and variables of
exposure were used for the multivariate analyses while
allowing for the independent effect of potential con-
founding factors. Statistical significance was set at <0.05.
Results
General characteristics of the sample population
Five hundred and ninety-eight patients were enrolled, of
which 42 were excluded as they did not fit the selection
criteria. The most important demographic and clinical
features of the patients referred to the specialist are pre-
sented in Table 1.
The sample was made up of young adults who were fairly
evenly distributed throughout Italy.
The majority of patients were enrolled at a follow-up
visit, while 35.8% of them were recruited on visit one.
Allergology (81.1%) and pulmonology (18.7%) were the most
predominant specialties of the prescribing doctors.House dust mite single allergic sensitization affected
around a third of the cases. The majority of patients were
receiving drug therapy and in a quarter of cases clinicians
judged the symptomology to be worsening.
The most common comorbidities were sinusitis and
gastroesophageal reflux disease.
SIT prescription: the role of ARIA and GINA
guideline recommendations
Though 556 patients met the selection criteria, only 513
questionnaires were completed correctly by patients and
were valid for the study.
Table 2 Distribution of the severity of comorbidity and of the prevalence of SIT prescription in all study participants. The
three subsets of the patient’s eligibility for SIT are underlined.
Severity of the concomitant rhinitis and asthma in the same patient Pts n: 513 (%) SIT n: 257 (%)
Not eligible for SIT
Mild intermittent rhinitis plus intermittent asthma 38 (7.4) 10 (3.9)
Mild intermittent rhinitis plus severe asthma 19 (3.7) 14 (5.4)
Eligible for one disease for SIT
Mild intermittent rhinitis plus mild persistent asthma 13 (2.5) 5 (1.9)
Mild intermittent rhinitis plus moderate persistent asthma 11 (2.1) 1 (0.4)
Moderate-severe intermittent rhinitis plus intermittent asthma 13 (2.5) 6 (2.3)
Moderate-severe intermittent rhinitis plus severe persistent asthma 4 (0.8) 1 (0.4)
Mild persistent rhinitis plus intermittent asthma 70 (13.6) 35(13.7)
Mild persistent rhinitis plus severe persistent asthma 33 (6.5) 18 (7)
Moderate-severe persistent rhinitis plus intermittent asthma 91(17.7) 51(19.8)
Moderate-severe persistent rhinitis plus severe persistent asthma 75(14.6) 41 (16)
Eligible for both diseases for SIT
Moderate-severe intermittent rhinitis plus mild persistent asthma 4 (0.8) 0
Moderate-severe intermittent rhinitis plus moderate persistent asthma 2 (0.4) 0
Mild persistent rhinitis plus mild persistent asthma 23 (4.5) 12 (4.7)
Mild persistent rhinitis plus moderate persistent asthma 30 (5.9) 11 (4.3)
Moderate-severe persistent rhinitis plus mild persistent asthma 33 (6.5) 26(10.1)
Moderate-severe persistent rhinitis plus moderate persistent asthma 54(10.5) 26(10.1)
1444 L. Antonicelli et al.Consistent with the ARIA and GINA guideline recommen-
dations, the majority of patients (89%) referred to
a specialist was eligible for SIT, based on the severity of one
disease only.
In order for the levels of severity of both diseases,
concomitant in the same patient, to match the ARIA and
GINA guideline recommendations, three subsets of
patients had to be formed (Table 2). The first group
included 57 patients (11%) non-eligible for SIT, because
the severity of both diseases did not meet the ARIA and
GINA criteria. The second group included 310 patients
(60%), who were eligible for SIT because of the severity of
one disease but not the other. The third group included
146 patients (29%) who met the recommendations for both
diseases.Figure 1 Percentage of SIT prescription in the three subsets
of eligibility, consistent with ARIA and GINA guidelines
recommendations.SIT was prescribed in 257 subjects (49.6%), this
percentage was roughly similar in each subset (Fig. 1). The
inappropriate prescription of SIT was limited (9.3% of the
total number of SIT prescriptions).
A statistically significant correlation (rZ 0.87;
c2pZ 0.001) between theprescription of SITand the severity
of rhinitis, consistent with ARIA recommendations, was
documented. A statistically significant difference
(c2pZ 0.02) in the prescription of SIT according to the
severity of asthma was recorded, though this trend was
inconsistent with the GINA recommendations (Table 3).
Analysis of the subsets confirmed the leading role of
rhinitis for SIT prescription (Table 2).Table 3 Prevalence of SIT prescription in each level of
disease severity consistent with ARIA and GINA guidelines.
Prescription of SIT
Yes, n (%) No, n (%)
Rhinitis severity (no. pts: 542)*
 Mild intermittent
 Moderate severe intermittent
 Mild persistent
 Moderate severe
persistent
32 (38.1) 52 (61.9)
8 (32.0) 17 (68.0)
79 (47.0) 89 (53.0)
154 (58.1) 111 (41.9)
Asthma severity (no. pts: 520)**
 Intermittent
 Mild persistent
 Moderate persistent
 Severe persistent
103 (48.4) 110 (51.6)
44 (58.7) 31 (41.3)
38 (38.8) 60 (61.2)
76 (56.7) 58 (43.4)
*c2pZ 0.001; **c2pZ 0.02.
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recommendations for each concomitant disease were con-
flicting, patients with an ARIA positive and GINA negative
profile (72.9% of patients) prevailed over those with an ARIA
negative and GINA positive profile.
SIT was prescribed in 67.2% of patients who met the ARIA
positive and GINA negative recommendations and in 25% of
patients who met the ARIA negative and GINA positive
recommendations (c2pZ 0.004).
Moreover, the prescription of SIT correlated with the
increase of the severity of rhinitis (7% of SIT prescriptions in
mod-severe-intermittent, 26% in mild persistent and 69% in
mod-severe persistent rhinitis) instead of the severity of
coexisting asthma (60.5% in intermittent asthma and 39.5%
in severe persistent asthma).
In the subset of eligible for both diseases patients, the
prescription of SIT goes up 48.8% consistent with the increase
of the severity of rhinitis instead of the severity of coexisting
asthma, even though the statistical significance was not
reached.SIT prescription: the interplay between
international guidelines and patient-tailored
approach
In addition to the guideline recommendations, other
factors potentially involved in decision to prescribe SIT
were evaluated (Table 4).
A statistically significant association between the
prescription of SIT and young age, mite monosensitisation,
current drug therapy, and the medical opinion of worsening
symptoms was documented.
Surprisingly, the reimbursement policies of the Regional
Health Services had no effect.
To assess the interplay between the guidelines and the
patient-tailored approach a bivariate analysis logistic
regression model was carried out (Table 5).
Young age was the most important independent factor
for SIT prescription in the two eligible patient subsets. In
the eligible for one disease subset, the probability of SIT
being prescribed was almost 6 times higher in teenagers,
and almost 3 times higher in the 21e50 age group than it
was in patients over 50 years.
In the eligible for both diseases patients once again the
probability of SIT being prescribed was 4.5 times higher in
the teenagers compared to the subsets of older patients.
In the eligible for one disease patient subset, the
disease’s tendency to worsen, as evaluated by the doctor,
was another independent factor for SIT prescription [OR 2.5
(95% CI, 1.403e4.542)].SIT prescription: the route of administration
SCITwas prescribed in 107 patients and SLIT in 150 patients.
The prevalence of SLIT was greater in each subset of
eligible patients (c2pZ 0.05) (data not shown). This finding
was consistent with the prevalent market share of SLIT in
Italy. No specific factor determining the choice of the route
of administration was documented.Discussion
Three main findings, concerning the congruence of SIT
prescription with guidelines recommendations, emerge
from this nationwide survey on mite allergic patients with
rhinitis and asthma comorbidity.The referral and the prescription of SIT
The majority of patients (89%) referred to specialist were
eligible for SIT, based on the severity of one disease, but
the single disease-oriented guidelines produced conflicting
recommendations for SIT, in the same patient, in more than
2/3 of cases.
Though not always openly admitted, the guidelines are
written for primary care doctors, which usually do not
prescribe SIT but refer the patient to the specialist.
Therefore, if the disease’s severity is considered
a marker for the specialist consultation our result confirms
the utility of the guideline recommendations, but this is no
longer the case if the guideline recommendations are
considered a marker for SIT prescription.
Because SIT is a single therapy effective for the treat-
ment of rhinitis and asthma, which often coexist in the
same patient with different level of severity, our result
underlines the quandary of the SIT prescription in the
severity-oriented guidelines framework.The specialist’s basis for SIT prescription
The almost equal levels of SIT prescription in the two
subsets of eligible for both diseases and eligible for one
disease patients, suggests a discrepancy between the ARIA
and GINA guidelines and the specialist’s intention to treat.
Our study provides evidence that the severity of rhinitis
and the age of the patient are the most important factors
underlining the decision to prescribe SIT.
We speculate that the aim of interfering with the
progression of the disease from the nose to the lower airways
and the aim of reducing the impact of rhinitis on asthma are
involved in this result. Indeed these are specific effects of SIT
on comorbidity, underlined by the SIT position papers.12e14
In the case of the former, the early commencement the
SIT was judged to be the best approach of interrupting the
allergic march, indeed in the bivariate logistic regression
model, young age was the most important independent
factor for SIT prescription, both in the eligible for one
disease and eligible for both diseases patients.12e14
Early intervention on the comorbidity is in line with this
purpose, as well.
Indeed, the most common condition for SIT prescription
(56%) in our survey was persistent rhinitis (both mild and
moderate-severe) with coexisting intermittent asthma
(Table 2).
Mite allergic rhinitis represents a major risk factor for
asthma, even in the adult population 15 and the ability of
SIT to interfere with the progression of the comorbidity was
shown.16,17
In the latter case, it has been shown that the asthma
control is more difficult to achieve when an uncontrolled
Table 4 Non-guidelines factors investigated in the
prescription of SIT.
Prescription of SIT
Yes, n (%) No, n (%)
Gender (no. pts 546)
 Male
 Female
124 (55.1) 101 (44.9)
152 (47.4) 169 (52.6)
Agexx (no. pts 547)
 20 yrs
 21< yrs 50
 >51
52 (60.5) 34 (39.5)
206 (51.1) 197 (48.9)
17 (29.3) 41 (70.7)
Comorbidity (no. pts 545)
 Yes
 No
56 (49.1) 58 (50.9)
218 (50.6) 213 (49.4)
Appointment (no. pts 542)
 First visit
 Follow-up
100 (51.3) 95 (48.7)
171 (49.3) 176 (50.7)
Sensitization* (no. pts 523)
 Monosensitive
 Polysensitive
96 (57.5) 71 (42.5)
167 (46.9) 189 (53.1)
Smoking status (no. pts 541)
 Never smoked
 Current
 Former
216 (52.2) 198 (47.8)
30 (42.3) 41 (57.7)
24 (42.9) 32 (57.1)
Drug therapy** (no. pts 543)
 Yes
 No
193 (53.9) 165 (46.1)
78 (42.2) 107 (57.8)
Education (no. pts 541)
 None
 Elementary school
 Middle school
 High school
 Ordinary degree
 Honours degree
 Master/specialization
2 (100) 0
13 (37.1) 22 (62.9)
85 (52.1) 78 (47.9)
126 (48.3) 135 (51.7)
11 (57.9) 8 (42.1)
31 (57.4) 23 (42.6)
6 (85.7) 1 (14.3)
Side effects to drug therapy (no. pts 424)
 Yes
 No
13 (44.8) 16 (55.2)
200 (50.6) 195 (49.4)
Tendency of the diseasexx (no. pts 524)
 No worsening
 Worsening
167 (43.8) 214 (56.2)
93 (65) 50 (35)
Specialist (no. pts 515)
 Allergist
 Pneumologist
 Other (internal medicine)
228 (54.4) 191 (45.6)
42 (44.2) 53 (55.8)
0 1 (100)
Payment (no. pts 489)
 Charged to patient
 Partially charged
to patient
 Not charged to patient
144 (53.3) 126 (46.7)
59 (57.8) 43 (42.2)
65 (55.6) 52 (44.4)
*c2pZ 0.024; xc2pZ 0.015; **c2pZ 0.009; xxc2p< 0.001.
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rhinitis improves the asthma control.19
On the other hand, the available drug therapy for rhinitis
is, not very effective for many patients,20 insomuch as
patients with moderate-severe persistent rhinitis, notwith-
standing coexisting treatment, are the majority of patients
referred to specialist setting.21,22
Our results show that the prescription of SIT follows the
increase in the severity of rhinitis instead of the severity of
coexisting asthma in both subsets of eligible for one disease
and eligible for both diseases patients (Table 2).
Moreover, in the subset of eligible for one disease
patients, in which SIT was most prescribed for the upper
airways share of comorbidity, the specialist’s belief that
the patient’s respiratory symptoms are worsening doubles
SIT prescription.
Taken together, these results suggest that the high
efficacy of SIT in mite allergic rhinitis23 is considered ful-
filling this unmet need of the therapy of severe allergic
rhinitis, particularly remarkable in the context of
comorbidity.24
This overriding concern for rhinitis undermines the congru-
ence of SIT prescription with the GINA guidelines, as well.
SITwas prescribed in 47.6% of asthmatics eligible for both
diseases for SIT, consistent with the GINA guidelines, but the
SIT prescription, driven by rhinitis severity, groups asth-
matics, whose asthma severity was outside the GINA
recommendations. In the eligible for one disease subset,
92.5% of asthmatics was outside the GINA recommendations.
Therefore in the real world, the approach of the
specialist to comorbidity partially fulfils the recommenda-
tions of the guidelines, in particular for asthma.The route of administration of SIT
The prevalence of SLIT prescriptions mirrors the market
share between the two routes of SIT administration in Italy.
The absence of any specific factor, determining the choice
of the route of administration is consistent with the
absence of any route-oriented recommendations in Italian
guidelines, to date. Equivalence or superiority trials
comparing SLIT and SCIT in mite allergic patients are lack-
ing; however the best evidence of efficacy is provided by
SCIT both in mite allergic rhinitis and in mite allergic
asthma.23,25e27
The main limitation of the study is that the extent of the
specialists’ knowledge of the guidelines, is unknown.
A recent French study documented ENT specialists’ partial
awareness of the ARIA guidelines, notwithstanding consid-
erable efforts to disseminate them.28 In Italy, a survey
performed in the same setting studied in this survey
(specialists belonging to AAITO) suggests good awareness of
the guidelines.12
In conclusion, the findings of our survey highlight the
discrepancy between the framework of disease-oriented
guidelines and the prescribing practices in mite allergic
patients, in the real world. Some distinctive feature of SIT,
not involved in the severity stepwise approach, seem to be
crucial points in the decision to prescribe SIT. Unfortunately,
their level of evidence in mite allergic patients with rhinitis
and asthma comorbidity is not yet totally satisfactory,16,17,29
Table 5 Logistical regression model to characterize the SIT prescription adjusting for guideline-driven and not guideline-
driven factor in the three subsets of the patient’s eligibility for SIT.
Factors OR IC p
Inf. Sup.
Not eligible for SIT
Monosensitive 1.899 0.299 12.060 Ns
Comorbidity 1.074 0.169 6.837 Ns
Tendency towards worsening 1.060 0.063 17.942 Ns
Payment (charged to
patient)
7.764 0.702 85.866 Ns
Presently undergoing drug
therapy
4.423 0.825 23.714 Ns
Gender 2.059 0.332 12.757 Ns
Age (20) 0.578 0.009 38.716 Ns
Age (>20 and 50) 3.580 0.355 36.079 Ns
Eligible for one disease for SIT
Monosensitive 1.734 0.967 3.108 Ns
Comorbidity 0.268 1.426 0.761 Ns
Tendency towards worsening 2.524 1.403 4.542 0.002
Payment (charged to
patient)
1.078 0.626 1.857 Ns
Presently undergoing drug
therapy
1.668 0.919 3.025 Ns
Gender 1.480 0.852 2.573 Ns
Age (20) 6.140 1.995 18.895 0.002
Age (>20 and 50) 2.973 1.193 7.408 0.019
Eligible for both diseases for SIT
Monosensitive 1.697 0.712 4.043 Ns
Comorbidity 0.991 0.381 2.577 Ns
Tendency towards worsening 1.636 0.648 4.131 Ns
Payment (charged to
patient)
0.521 0.244 1.114 Ns
Presently undergoing drug
therapy
1.318 0.489 3.551 Ns
Gender 1.247 0.578 2.689 Ns
Age (20) 4.532 1.029 19.959 0.046
Age (>20 and 50) 1.721 0.487 6.085 Ns
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cally designed for the mite respiratory allergy.
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